fda anda stats, page-8

Roger10/Tana, good on management for doing what they have done, whether they knew of delay or not. They have successfully kept ACL's future alive for not only Generic Fonda but they have kept the HA dream alive and into a phase 3 trial not to mention the Lung cancer phase 2. Question many will but all in all managements job is to grow the company however it can and let due course take its toll.

At this stage of the game I find it a laugh that some wish to attack management when all they are employed to do and all they aim to do is make a major success out of the company against all odds that face them, not a bad thing when the majority fail to do so.

The future is very close for ACL, we may see many Fund Managers and Brokers with interests in ACL, we will see very many interesting times especially with the growth factor of Fonda and the potential of HA-Irinotecan amongst everything else.

Good luck all....................